The company has been examining in greater detail how often the treatment may need to be administered, with a focus on identifying an optimal dosing regimen as it prepares the next stage of clinical development and regulatory engagement.
Noxopharm advances lupus therapy with data pointing to durable skin targeting and low systemic exposure
April 22, 2026 Australian Biotech
Latest Video
New Stories
-
LENZ and Arrotex partner to bring once daily presbyopia treatment to Australia and New Zealand
June 25, 2026 - - Latest News -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New Zealand last among peers for publicly funded modern medicines
June 25, 2026 - - Latest News -
A 'Stronger PBS' makes way for 'We are now in a fight to save the PBS'
June 25, 2026 - - Latest News -
Early real world data shows improvement in treatment resistant depression
June 24, 2026 - - Latest News -
FDA backs AFT’s injectable iron into Phase 3 study as company targets global scale
June 24, 2026 - - Latest News


